PTC Therapeutics, Inc. Operating Lease, Payments
PTC Therapeutics, Inc. (PTCT) reported Operating Lease, Payments of $16.56 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-02-19
- PTC Therapeutics, Inc. operating lease, payments for the quarter ending 2025-12-31 was $4.31M, a 8.81% increase year-over-year.
- PTC Therapeutics, Inc. operating lease, payments for the quarter ending 2025-09-30 was $4.71M, a 8.35% increase year-over-year.
- PTC Therapeutics, Inc. operating lease, payments for the quarter ending 2025-06-30 was $4.15M, a 11.12% decline year-over-year.
- PTC Therapeutics, Inc. operating lease, payments for the quarter ending 2025-03-31 was $3.39M, a 14.16% decline year-over-year.
- PTC Therapeutics, Inc. operating lease, payments for fiscal 2025 was $16.56M, a 2.16% decline from fiscal 2024.
- PTC Therapeutics, Inc. operating lease, payments for fiscal 2024 was $16.92M, a 10.34% increase from fiscal 2023.
- PTC Therapeutics, Inc. operating lease, payments for fiscal 2023 was $15.34M, a 4.09% increase from fiscal 2022.
- PTC Therapeutics, Inc. operating lease, payments for fiscal 2022 was $14.74M, a 7.70% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $9.02M derived: sum of 2 quarters · filed 2026-02-19 | $13.17M derived: sum of 3 quarters · filed 2026-02-19 | $16.56M 10-K · filed 2026-02-19 |
| 2025-09-30 | $4.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $8.86M derived: sum of 2 quarters · filed 2025-11-04 | $12.25M 10-Q · filed 2025-11-04 | $16.21M derived: sum of 4 quarters · filed 2026-02-19 |
| 2025-06-30 | $4.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $7.54M 10-Q · filed 2025-08-07 | $11.50M derived: sum of 3 quarters · filed 2026-02-19 | $15.85M derived: sum of 4 quarters · filed 2026-02-19 |
| 2025-03-31 | $3.39M 10-Q · filed 2025-05-06 | $7.35M derived: sum of 2 quarters · filed 2026-02-19 | $11.70M derived: sum of 3 quarters · filed 2026-02-19 | $16.36M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-12-31 | $3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $8.31M derived: sum of 2 quarters · filed 2026-02-19 | $12.98M derived: sum of 3 quarters · filed 2026-02-19 | $16.92M 10-K · filed 2026-02-19 |
| 2024-09-30 | $4.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $9.02M derived: sum of 2 quarters · filed 2025-11-04 | $12.96M 10-Q · filed 2025-11-04 | $16.82M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $4.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $8.62M 10-Q · filed 2025-08-07 | $12.48M derived: sum of 3 quarters · filed 2026-02-19 | $16.33M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $3.95M 10-Q · filed 2025-05-06 | $7.81M derived: sum of 2 quarters · filed 2026-02-19 | $11.66M derived: sum of 3 quarters · filed 2026-02-19 | $15.47M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $7.71M derived: sum of 2 quarters · filed 2026-02-19 | $11.53M derived: sum of 3 quarters · filed 2026-02-19 | $15.34M 10-K · filed 2026-02-19 |
| 2023-09-30 | $3.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $7.67M derived: sum of 2 quarters · filed 2024-11-07 | $11.48M 10-Q · filed 2024-11-07 | $15.26M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $3.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $7.62M 10-Q · filed 2024-08-08 | $11.41M derived: sum of 3 quarters · filed 2025-02-27 | $15.27M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $3.81M 10-Q · filed 2024-04-25 | $7.59M derived: sum of 2 quarters · filed 2025-02-27 | $11.46M derived: sum of 3 quarters · filed 2025-02-27 | $15.14M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $3.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $7.65M derived: sum of 2 quarters · filed 2025-02-27 | $11.32M derived: sum of 3 quarters · filed 2025-02-27 | $14.74M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $7.54M derived: sum of 2 quarters · filed 2023-10-26 | $10.95M 10-Q · filed 2023-10-26 | $14.38M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $3.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $7.09M 10-Q · filed 2023-08-03 | $10.52M derived: sum of 3 quarters · filed 2024-02-29 | $13.96M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $3.41M 10-Q · filed 2023-04-27 | $6.84M derived: sum of 2 quarters · filed 2024-02-29 | $10.28M derived: sum of 3 quarters · filed 2024-02-29 | $13.69M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $3.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $6.87M derived: sum of 2 quarters · filed 2024-02-29 | $10.28M derived: sum of 3 quarters · filed 2024-02-29 | $13.68M 10-K · filed 2024-02-29 |
| 2021-09-30 | $3.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $6.85M derived: sum of 2 quarters · filed 2022-10-27 | $10.25M 10-Q · filed 2022-10-27 | $13.11M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $3.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $6.82M 10-Q · filed 2022-08-04 | $9.67M derived: sum of 3 quarters · filed 2023-02-21 | $11.86M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $3.41M 10-Q · filed 2022-05-03 | $6.26M derived: sum of 2 quarters · filed 2023-02-21 | $8.45M derived: sum of 3 quarters · filed 2023-02-21 | $9.90M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $5.05M derived: sum of 2 quarters · filed 2023-02-21 | $6.49M derived: sum of 3 quarters · filed 2023-02-21 | $8.46M 10-K · filed 2023-02-21 |
| 2020-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $3.64M derived: sum of 2 quarters · filed 2021-10-28 | $5.61M 10-Q · filed 2021-10-28 | $7.33M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $3.41M 10-Q · filed 2021-07-29 | $5.13M derived: sum of 3 quarters · filed 2022-02-22 | $6.37M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $1.97M 10-Q · filed 2021-05-04 | $3.69M derived: sum of 2 quarters · filed 2022-02-22 | $4.93M derived: sum of 3 quarters · filed 2022-02-22 | $5.71M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $2.96M derived: sum of 2 quarters · filed 2022-02-22 | $3.73M derived: sum of 3 quarters · filed 2022-02-22 | $4.47M 10-K · filed 2022-02-22 |
| 2019-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $2.02M derived: sum of 2 quarters · filed 2020-10-29 | $2.75M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $776.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.51M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $732.00K 10-Q · filed 2020-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |